Patents by Inventor Robert J. Hariri

Robert J. Hariri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8916146
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 23, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Publication number: 20140349391
    Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
    Type: Application
    Filed: June 6, 2014
    Publication date: November 27, 2014
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Patent number: 8895256
    Abstract: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: November 25, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: Casper Paludan, James Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert J. Hariri
  • Patent number: 8889411
    Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: November 18, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, David I. Stirling, Laure A. Moutouh-De Parseval, Kyle W. H. Chan
  • Publication number: 20140322175
    Abstract: The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 30, 2014
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Patent number: 8753883
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 17, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 8691217
    Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 8, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
  • Publication number: 20140093488
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: August 13, 2012
    Publication date: April 3, 2014
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20140072538
    Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of, and compositions comprising, such cells.
    Type: Application
    Filed: July 12, 2013
    Publication date: March 13, 2014
    Inventors: Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
  • Publication number: 20140017211
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Application
    Filed: September 16, 2013
    Publication date: January 16, 2014
    Applicant: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Patent number: 8617535
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: December 31, 2013
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20130344037
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 26, 2013
    Applicant: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 8591883
    Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 26, 2013
    Assignee: Anthrogenesis Corporation
    Inventors: James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
  • Patent number: 8580563
    Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: November 12, 2013
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Patent number: 8562972
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: October 22, 2013
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Publication number: 20130259845
    Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 3, 2013
    Applicant: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
  • Patent number: 8545833
    Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: October 1, 2013
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20130230497
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: April 15, 2013
    Publication date: September 5, 2013
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Patent number: 8460650
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: June 11, 2013
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 8435788
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: May 7, 2013
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri